Solomon T Gizaw1, Tetsu Ohashi2, Masakazu Tanaka2, Hiroshi Hinou3, Shin-Ichiro Nishimura4. 1. Field of Drug Discovery Research, Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University, N21 W11, Sapporo 001-0021, Japan. 2. Medicinal Chemistry Pharmaceuticals, Co., Ltd, N21 W12, Sapporo 001-0021, Japan. 3. Field of Drug Discovery Research, Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University, N21 W11, Sapporo 001-0021, Japan; Medicinal Chemistry Pharmaceuticals, Co., Ltd, N21 W12, Sapporo 001-0021, Japan. 4. Field of Drug Discovery Research, Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University, N21 W11, Sapporo 001-0021, Japan; Medicinal Chemistry Pharmaceuticals, Co., Ltd, N21 W12, Sapporo 001-0021, Japan. Electronic address: shin@sci.hokudai.ac.jp.
Abstract
BACKGROUND: Understanding of the significance of posttranslational glycosylation in Alzheimer's disease (AD) is of growing importance for the investigation of the pathogenesis of AD as well as discovery research of the disease-specific serum biomarkers. METHODS: We designed a standard protocol for the glycoblotting combined with MALDI-TOFMS to perform rapid and quantitative profiling of the glycan parts of glycoproteins (N-glycans) and glycosphingolipids (GSLs) using human AD's post-mortem samples such as brain tissues (dissected cerebral cortices such as frontal, parietal, occipital, and temporal domains), serum and cerebrospinal fluid (CSF). RESULTS: The structural profiles of the major N-glycans released from glycoproteins and the total expression levels of the glycans were found to be mostly similar between the brain tissues of the AD patients and those of the normal control group. In contrast, the expression levels of the serum and CSF protein N-glycans such as bisect-type and multiply branched glycoforms were increased significantly in AD patient group. In addition, the levels of some gangliosides such as GM1, GM2 and GM3 appeared to alter in the AD patient brain and serum samples when compared with the normal control groups. CONCLUSION: Alteration of the expression levels of major N- and GSL-glycans in human brain tissues, serum and CSF of AD patients can be monitored quantitatively by means of the glycoblotting-based standard protocols. GENERAL SIGNIFICANCE: The changes in the expression levels of the glycans derived from the human post-mortem samples uncovered by the standardized glycoblotting method provides potential serum biomarkers in central nervous system disorders and can contribute to the insight into the molecular mechanisms in the pathogenesis of neurodegenerative diseases and future drug discovery. Most importantly, the present preliminary trials using human post-mortem samples of AD patients suggest that large-scale serum glycomics cohort by means of various-types of human AD patients as well as the normal control sera can facilitate the discovery research of highly sensitive and reliable serum biomarkers for an early diagnosis of AD. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.
BACKGROUND: Understanding of the significance of posttranslational glycosylation in Alzheimer's disease (AD) is of growing importance for the investigation of the pathogenesis of AD as well as discovery research of the disease-specific serum biomarkers. METHODS: We designed a standard protocol for the glycoblotting combined with MALDI-TOFMS to perform rapid and quantitative profiling of the glycan parts of glycoproteins (N-glycans) and glycosphingolipids (GSLs) using humanAD's post-mortem samples such as brain tissues (dissected cerebral cortices such as frontal, parietal, occipital, and temporal domains), serum and cerebrospinal fluid (CSF). RESULTS: The structural profiles of the major N-glycans released from glycoproteins and the total expression levels of the glycans were found to be mostly similar between the brain tissues of the ADpatients and those of the normal control group. In contrast, the expression levels of the serum and CSF protein N-glycans such as bisect-type and multiply branched glycoforms were increased significantly in ADpatient group. In addition, the levels of some gangliosides such as GM1, GM2 and GM3 appeared to alter in the ADpatient brain and serum samples when compared with the normal control groups. CONCLUSION: Alteration of the expression levels of major N- and GSL-glycans in human brain tissues, serum and CSF of ADpatients can be monitored quantitatively by means of the glycoblotting-based standard protocols. GENERAL SIGNIFICANCE: The changes in the expression levels of the glycans derived from the human post-mortem samples uncovered by the standardized glycoblotting method provides potential serum biomarkers in central nervous system disorders and can contribute to the insight into the molecular mechanisms in the pathogenesis of neurodegenerative diseases and future drug discovery. Most importantly, the present preliminary trials using human post-mortem samples of ADpatients suggest that large-scale serum glycomics cohort by means of various-types of humanADpatients as well as the normal control sera can facilitate the discovery research of highly sensitive and reliable serum biomarkers for an early diagnosis of AD. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.
Authors: Motamed Elsayed Mahmoud; Ibrahim F Rehan; Kh El-Dawy Ahmed; Amany Abdelrahman; Saeed Mohammadi; Ahmed F Abou-Elnaga; Mohammed Youssef; Hassan Mahmoud Diab; Doaa Salman; Asmaa Elnagar; Hesham H Mohammed; Obeid Shanab; Rawia M Ibrahim; Eslam K H Ahmed; Abd El-Latif Hesham; Arti Gupta Journal: Mol Biol Rep Date: 2019-03-26 Impact factor: 2.316
Authors: Calvin R K Blaschke; Colin T McDowell; Alyson P Black; Anand S Mehta; Peggi M Angel; Richard R Drake Journal: Clin Lab Med Date: 2021-04-24 Impact factor: 2.172
Authors: Alexandre Henriques; Mylene Huebecker; Hélène Blasco; Céline Keime; Christian R Andres; Philippe Corcia; David A Priestman; Frances M Platt; Michael Spedding; Jean-Philippe Loeffler Journal: Sci Rep Date: 2017-07-12 Impact factor: 4.379